Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial

Article English OPEN
Solomon, Scott D. ; Claggett, Brian ; Packer, Milton ; Desai, Akshay ; Zile, Michael R. ; Swedberg, Karl ; Rouleau, Jean ; Shi, Victor ; Lefkowitz, Martin ; McMurray, John J.V. (2016)

Objectives: \ud \ud This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability.\ud \ud Background: \ud \ud Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should be delayed until occurrence of clinical decompensation.\ud \ud Methods: \ud \ud Outcomes were compared among patients who had prior hospitalization within 3 months of screening (n = 1,611 [19%]), between 3 and 6 months (n = 1,009 [12%]), between 6 and 12 months (n = 886 [11%]), >12 months (n = 1,746 [21%]), or who had never been hospitalized (n = 3,125 [37%]).\ud \ud Results: \ud \ud Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular death or heart failure (HF) hospitalization during the course of the trial. Despite the increased risk associated with more recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect to cardiovascular or all-cause mortality.\ud \ud Conclusions: \ud \ud Patients with recent HF decompensation requiring hospitalization were more likely to experience cardiovascular death or HF hospitalization than those who had never been hospitalized. Patients who were clinically stable, as shown by a remote HF hospitalization (>3 months prior to screening) or by lack of any prior HF hospitalization, were as likely to benefit from sacubitril/valsartan therapy as more recently hospitalized patients. (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).
  • References (10)

    1. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF 2014;2:663-70.

    2. McMurray JJ, Packer M, Desai AS, et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.

    3. Simpson J, Jhund PS, Cardoso JS, et al. Effect of LCZ696, compared with enalapril, according to baseline risk in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). J Am Coll Cardiol 2015;66: 2059-71.

    4. Solomon SD, Claggett B, Desai A, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: the PARADIGM-HF trial. Circ Heart Fail 2016;9(3): e002744.

    5. Murray A. PL Detail-Document, New Drug: Entresto (Sacubitril/Valsartan). Pharmacist's Letter/Prescriber's Letter. September 2015. Available at: http://prescribersletter.therapeuticresearch. com/pl/ArticlePDF.aspx?cs=&s=PRL&DocumentFile ID=0&DetailID=310919&SegmentID=0%20usg¼ AFQjCNHlwDjwIfMoXThziRtRcxAQR0tlrg. Accessed May 26,2016

    6. Bello NA, Claggett B, Desai AS, et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail 2014;7: 590-5.

    Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062-73.

    8. Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 2014;8: 141-7.

    9. Giugliano D, Esposito K. Clinical inertia as a clinical safeguard. JAMA 2011;305:1591-2.

    7. McMurray JJ, Packer M, Desai AS, et al., PARADIGM-HF Committees and Investigators.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark